Tolvaptan-Octreotide LAR Combination in ADPKD

NCT03541447 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Autosomal Dominant Polycystic Kidney Disease

Interventions

DRUG: Tolvaptan
DRUG: Octreotide LAR
OTHER: Placebo

Sponsor

Mario Negri Institute for Pharmacological Research

Collaborators

[object Object]